Literature DB >> 11821398

Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor.

Houping Ni1, John Capodici, Georgetta Cannon, Didier Communi, Jean-Marie Boeynaems, Katalin Karikó, Drew Weissman.   

Abstract

We previously demonstrated that dendritic cell (DC) pulsing with antigen-encoded mRNA resulted in the loading of both major histocompatibility complex class I and II antigen presentation pathways and the delivery of an activation signal. Coculture of mRNA-pulsed DC with T cells led to the induction of a potent primary immune response. DC, in addition to recognizing foreign antigens through pattern recognition receptors, also must respond to altered self, transformed, or intracellularly infected cells. This occurs through cell surface receptors that recognize products of inflammation and cell death. In this report, we characterize two signaling pathways utilized by extracellular mRNA to activate DC. In addition, a novel ligand, poly(A), is identified that mediates signaling through a receptor that can be inhibited by pertussis toxin and suramin and can be desensitized by ATP and ADP, suggesting a P2Y type nucleotide receptor. The role of this signaling activity in vaccine design and the potential effect of mRNA released by damaged cells in the induction of immune responsiveness is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821398     DOI: 10.1074/jbc.M110729200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes.

Authors:  John K Hermann; Jeffrey R Capadona
Journal:  Crit Rev Biomed Eng       Date:  2018

Review 2.  The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.

Authors:  Miroslaw Janowski; Anna Andrzejewska
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

3.  Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses.

Authors:  Uwe Koedel; Ulrike Michaela Merbt; Caroline Schmidt; Barbara Angele; Bernadette Popp; Hermann Wagner; Hans-Walter Pfister; Carsten J Kirschning
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 4.  Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.

Authors:  Kenneth R Chien; Lior Zangi; Kathy O Lui
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

5.  A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.

Authors:  Christiane Geiger; Sybille Regn; Andreas Weinzierl; Elfriede Noessner; Dolores J Schendel
Journal:  J Transl Med       Date:  2005-07-26       Impact factor: 5.531

Review 6.  Advances in the design and development of SARS-CoV-2 vaccines.

Authors:  Xue-Liang Peng; Ji-Si-Yu Cheng; Hai-Lun Gong; Meng-Di Yuan; Xiao-Hong Zhao; Zibiao Li; Dai-Xu Wei
Journal:  Mil Med Res       Date:  2021-12-16

7.  Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.

Authors:  Stefanie Hoyer; Kerstin F Gerer; Isabell A Pfeiffer; Sabrina Prommersberger; Sandra Höfflin; Tanushree Jaitly; Luca Beltrame; Duccio Cavalieri; Gerold Schuler; Julio Vera; Niels Schaft; Jan Dörrie
Journal:  J Immunol Res       Date:  2015-12-28       Impact factor: 4.818

8.  Large Differences in Small RNA Composition Between Human Biofluids.

Authors:  Paula M Godoy; Nirav R Bhakta; Andrea J Barczak; Hakan Cakmak; Susan Fisher; Tippi C MacKenzie; Tushar Patel; Richard W Price; James F Smith; Prescott G Woodruff; David J Erle
Journal:  Cell Rep       Date:  2018-10-30       Impact factor: 9.423

Review 9.  Paving the Road for RNA Therapeutics.

Authors:  Niels Dammes; Dan Peer
Journal:  Trends Pharmacol Sci       Date:  2020-09-03       Impact factor: 14.819

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.